EUCTR2007-007749-11-DE进行中（未招募）不适用
An open-label, randomized, multicenter, two-arm efficacy and safety study of 14 daystreatment with Finafloxacin 400 mg b.i.d. plus Amoxicillin 1000 mg b.i.d.versus Finafloxacin 400 mg b.i.d. plus Esomeprazole 40 mg b.i.d. in patients withHelicobacter pylori infectionFinafloxacin in patients with Helicobacter: FLASH study - FLASH
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients of 18 to 70 years old, with dyspepsia or dyspeptic
- •2. The patient must understand the nature of the study and must provide written
- •informed consent.
- •3. Each patient must be able to communicate with study personnel.
- •4. Gastroscopic confirmation of H. pylori infection by Rapid Urease Test.
- •5. Positive Urea Breath Test.
- •6. Absence of blood in stools.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Gastroscopic confirmation of gastric ulcers.
- •2. History of Zollinger-Ellison syndrome.
- •3. Gastroesophageal Reflux Disease (GERD).
- •4. Subtotal gastrectomy or vagotomy in medical history.
- •5. Pyloric stenosis.
- •6. Previous H. pylori eradication therapy.
- •7. Patients likely to need to take one of the following medication within two weeks
- •prior to and during the study period:
- •any other antibiotic than the study medication;
- •any other proton-pump inhibitor than the study medication;
- •NSAIDs including aspirin and glucocorticoids.
- •8. Patients taking antacids and/or H2-blockers during the study period.
- •9. Patients taking bismuth compound within four weeks prior to and during the study period.
- •10. Patients with psychiatric, neurological, or behavioral disorders that may interfere with the conduct or interpretation of the study.
- •11. Patients with severe concomitant disease of the cardiovascular, pulmonic, hepatic, renal, hematologic, lymphatic, metabolic and endocrine system.
- •12. Clinically significant serious unstable physical illness: treated, controlled and thus stable hypertension is not considered an exclusion criterion.
- •13. Patients with known uncontrolled hypertension or symptomatic hypotension.
- •14. Patients who are immunocompromised.
- •15. Patients with malignant disease of any kind except Basalioma.
- •16. Patients showing clinically significant abnormal vital signs.
- •17. Patients with clinically significant abnormal ECG findings.
- •18. Clinically significant abnormal laboratory data at Screening, or any abnormal
- •laboratory value that could interfere with the assessment of safety.
- •19. Exposure to any investigational drug within 30 days prior Screening.
- •20. Known hypersensitivity or contraindication to the use of fluoroquinolones.
- •21. Prior participation in Finafloxacin study.
- •22. Pregnant or nursing woman, or woman of childbearing potential who is not
- •using an effective contraceptive method during the study, e.g. oral (stable doses for at least three months prior to Screening) or injectable (stable doses for at least two months prior to Screening) contraceptives, implantation of levonorgestrel system and intrauterine devices (for at least two months prior Screening), barrier methods (combination of diaphragm and spermicide or condom and spermicide).
- •23. Current diagnosis or known history of substance abuse.
- •24. Site personnel and their immediate families, defined as their spouse, parent,
- •child, grandparent or grandchild.
- •25. Reasonable likelihood for non-compliance with the protocol or any other reason
- •that, in the investigator’s opinion, prohibits the inclusion of the patient into the study.
研究者
相似试验
招募中
2 期
Randomized controlled trial of a cognitive behavioral therapy application for insomnia (IIIP MED: Sleepy Med)Insomnia disorderinsomnia disorderInsomnia DisorderJPRN-jRCT2032230353Shimizu Eiji30
招募中
1 期
A food effects trial of the pharmacokinetics of brexpiprazole once-weekly (QW) formulation in patients with schizophreniaschizophreniaJPRN-jRCT2071230059Matsumaru Takehisa50
进行中（未招募）
不适用
A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparison to simvastatin therapy alone in inhibiting the progression of atherosclerosis in patients with carotid arteries stenosis and dyslipidemia.EUCTR2014-003213-29-PLSciencePharma spólka z ograniczona odpowiedzialnoscia sp. j.
已完成
3 期
A study of tacrolimus suspension of Intas Pharmaceuticals Limited, India against CORTENEMA® of Anip Acquisition Company, USA in adult patients with inflammation in the digestive tract.CTRI/2019/04/018626Intas Pharmaceuticals Limited
进行中（未招募）
1 期
se of umbilical cord eye drops in neurotrophic keratopathyeurotrophic Keratitis, stage 2 or 3MedDRA version: 19.0Level: PTClassification code 10064996Term: Ulcerative keratitisSystem Organ Class: 10015919 - Eye disordersEUCTR2016-001841-23-ESBanc de Sang i Teixits42